Improved survival outcomes with the addition of rituximab to initial therapy for chronic lymphocytic leukemia: a comparative effectiveness analysis in the province of British Columbia, Canada.

摘要: Chemoimmunotherapy with rituximab improves survival in clinical trials upfront chronic lymphocytic leukemia (CLL) treatment. This study compared outcomes and without added to first-line chemotherapy a provincial cohort of CLL patients. Between 1973 2014, 1345 patients received treatment: 48% rituximab, 52% alone. Median overall (OS) treatment-free (TFS) were significantly longer rituximab: OS 8.9 vs. 6.2 years, p < .0001; TFS 3.6 2.1 p < .0001. Addition was strong independent predictor mortality 32% reduction after controlling for co-variates (age, sex, stage, treatment purine analogs). large population-based complements trial registry data demonstrating the benefit adding therapy adds further evidence efficacy rituximab-based chemoimmunotherapy real-world setting.